Eurobio Scientific SA
PAR:ALERS
Eurobio Scientific SA
Total Liabilities
Eurobio Scientific SA
Total Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Eurobio Scientific SA
PAR:ALERS
|
Total Liabilities
€135.1m
|
CAGR 3-Years
43%
|
CAGR 5-Years
28%
|
CAGR 10-Years
19%
|
|
|
Valneva SE
PAR:VLA
|
Total Liabilities
€318.8m
|
CAGR 3-Years
-21%
|
CAGR 5-Years
20%
|
CAGR 10-Years
12%
|
|
|
Nanobiotix SA
PAR:NANO
|
Total Liabilities
€108.5m
|
CAGR 3-Years
10%
|
CAGR 5-Years
15%
|
CAGR 10-Years
38%
|
|
|
Innate Pharma SA
PAR:IPH
|
Total Liabilities
€122.7m
|
CAGR 3-Years
-3%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
21%
|
|
|
G
|
Genfit SA
PAR:GNFT
|
Total Liabilities
€97.4m
|
CAGR 3-Years
-1%
|
CAGR 5-Years
-16%
|
CAGR 10-Years
17%
|
|
|
Inventiva SA
PAR:IVA
|
Total Liabilities
€118.5m
|
CAGR 3-Years
60%
|
CAGR 5-Years
44%
|
CAGR 10-Years
N/A
|
|
Eurobio Scientific SA
Glance View
Eurobio-Scientific SA engages in designing, development and commercialization of tests diagnosis in the fields of transplantation, infectious diseases, autoimmunity and oncology, as well as products for research in the field of life sciences. The company is headquartered in Les Ulis, Ile-De-France. The company went IPO on 2005-11-18. The company is engaged in activities ranging from discovery to the commercialization of specialty diagnostic products. The firm owns a portfolio of diagnostic products in three specialty areas: infectious diseases; Alzheimer's disease, and cancer. The company consists of Tetanos Quick Stick (TQS), which is an unitary test enabling to determine the tetanus vaccination status. The company has a portfolio of in-house and co-developed products, including AclarusDx (a blood-based test for the detection of biomarkers specific for Alzheimer's disease). The portfolio includes BJI Inoplex for prosthetic infections and EHT Dx14 for breast cancer (both in validation phase). The co-developed products include research programs for the identification of predictive biomarkers of response for anti-HER2 and anti-angiogenic therapies, among others. The company operates through Genbio and Eurobio Capforce Plus.
See Also
What is Eurobio Scientific SA's Total Liabilities?
Total Liabilities
135.1m
EUR
Based on the financial report for Jun 30, 2024, Eurobio Scientific SA's Total Liabilities amounts to 135.1m EUR.
What is Eurobio Scientific SA's Total Liabilities growth rate?
Total Liabilities CAGR 10Y
19%
Over the last year, the Total Liabilities growth was -2%. The average annual Total Liabilities growth rates for Eurobio Scientific SA have been 43% over the past three years , 28% over the past five years , and 19% over the past ten years .
You don't have any saved screeners yet